U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H28FN5O2.C7H8O3S
Molecular Weight 537.647
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BESIGLIPTIN TOSYLATE

SMILES

CC1=CC=C(C=C1)S(O)(=O)=O.[H][C@@]23CN(C[C@]2([H])C[C@](C)(C3)NCC(=O)N4C[C@@H](F)C[C@H]4C#N)C(=O)N(C)C

InChI

InChIKey=VBMNNLBIPDGFBS-XGXURLCGSA-N
InChI=1S/C18H28FN5O2.C7H8O3S/c1-18(21-8-16(25)24-11-14(19)4-15(24)7-20)5-12-9-23(10-13(12)6-18)17(26)22(2)3;1-6-2-4-7(5-3-6)11(8,9)10/h12-15,21H,4-6,8-11H2,1-3H3;2-5H,1H3,(H,8,9,10)/t12-,13+,14-,15-,18+;/m0./s1

HIDE SMILES / InChI
Molecular Formula C7H8O3S
Molecular Weight 172.202
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C18H28FN5O2
Molecular Weight 365.4456
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Jiangsu HengRui Medicine Co. is developing SHR-117887, an orally active dipeptidyl peptidase-4 (CD26 antigen) inhibitor for the treatment of type 2 diabetes. SHR-117887 is a potent DPP-4 inhibitor that improves metabolic control and β-cell function in diabetic rodent models. SHR-117887 is in phase II clinical trials for the treatment of type 2 diabetes.

Originator

Approval Year

Unknown
139594
PubMed

PubMed

TitleDatePubMed
Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models.
2012 Aug
Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases.
2019 Mar

Sample Use Guides

In Vivo Use Guide
Type 2 Diabetes: Experimental: SHR-117887 (50mg q.d)/Metformin Patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period. After randomised,patients adminitered SHR117887 50mg QD and metformin 500mg TID for 12 weeks. Experimental: SHR-117887 (100mg q.d)/Metformin patients are administered oral placebo once daily and metformin 500mg TID for 4 weeks at the run-in period.After randomised, patients adminitered SHR-117887 100mg QD and metformin 500mg TID for 12 weeks.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:52:17 GMT 2023
Edited
by admin
on Sat Dec 16 11:52:17 GMT 2023
Record UNII
06SMN21EQE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BESIGLIPTIN TOSYLATE
Common Name English
SHR-117887
Common Name English
(3AS,6AR)-5-((2-((2S,4S)-2-CYANO-4-FLUORO-PYRROLIDIN-1-YL)-2-OXO-ETHYL)AMINO)-N,N,5-TRIMETHYL-1,3,3A,4,6,6A-HEXAHYDROCYCLOPENTA(C)PYRROLE-2-CARBOXAMIDE; 4-METHYLBENZENESULFONIC ACID
Systematic Name English
CYCLOPENTA(C)PYRROLE-2(1H)-CARBOXAMIDE, 5-((2-((2S,4S)-2-CYANO-4-FLUORO-1-PYRROLIDINYL)-2-OXOETHYL)AMINO)HEXAHYDRO-N,N,5-TRIMETHYL-, (3A.ALPHA.,5.ALPHA.,6A.ALPHA.)-, 4-METHYLBENZENESULFONATE (1:1)
Systematic Name English
SHR117887
Code English
Code System Code Type Description
FDA UNII
06SMN21EQE
Created by admin on Sat Dec 16 11:52:17 GMT 2023 , Edited by admin on Sat Dec 16 11:52:17 GMT 2023
PRIMARY
CAS
1177460-72-8
Created by admin on Sat Dec 16 11:52:17 GMT 2023 , Edited by admin on Sat Dec 16 11:52:17 GMT 2023
PRIMARY
PUBCHEM
91667592
Created by admin on Sat Dec 16 11:52:17 GMT 2023 , Edited by admin on Sat Dec 16 11:52:17 GMT 2023
PRIMARY
Related Record Type Details
Structure of BESIGLIPTIN
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of BESIGLIPTIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966